Juno Diagnostics (JunoDx), a company focused on improving access to genetic health information, announced the closing of an expanded Series A financing round of $25 million led by the Perceptive Xontogeny Venture (PXV) Fund.

Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The company's lead product is an NIPT solution that simplifies sample collection and improves access to high quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT.